Report Summarizes Respiratory Syncytial Viruses Study Findings from Children's Hospital Philadelphia (Improvement In Palivizumab Administration Prior To Discharge for Hospitalized Infants With Hemodynamically Significant Congenital Heart...).

Předmět:	PALIVIZUMAB RESPIRATORY syncytial virus CHILDREN'S hospitals CONGENITAL heart disease INFANTS
Zdroj:	Heart Disease Weekly; 6/5/2023, p1353-1353, 1p
Abstrakt:	Keywords: Philadelphia; State:Pennsylvania; United States; North and Central America; Antiinfectives; Antivirals; Biotechnology; Cardiology; Cardiovascular Diseases and Conditions; Congenital Diseases and Conditions; Congenital Heart Disease; Drugs and Therapies; Health and Medicine; Heart Disease; Heart Disorders and Diseases; Hospitals; Immune Globulins; Immunologic Agents; Monoclonal Antibodies; Palivizumab Therapy; Pharmaceuticals; RNA Viruses; Respiratory Syncytial Viruses; Risk and Prevention; Viral; Virology EN Philadelphia State:Pennsylvania United States North and Central America Antiinfectives Antivirals Biotechnology Cardiology Cardiovascular Diseases and Conditions Congenital Diseases and Conditions Congenital Heart Disease Drugs and Therapies Health and Medicine Heart Disease Heart Disorders and Diseases Hospitals Immune Globulins Immunologic Agents Monoclonal Antibodies Palivizumab Therapy Pharmaceuticals RNA Viruses Respiratory Syncytial Viruses Risk and Prevention Viral Virology 1353 1353 1 06/05/23 20230605 NES 230605 2023 JUN 9 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- New research on RNA Viruses - Respiratory Syncytial Viruses is the subject of a report. We included 470 infants over four respiratory syncytial virus (RSV) seasons from 11/2017 to 03/2021 (baseline season: 11/2017-03/2018).". [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu